---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-284671"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:20:49.303944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics raises $30M via registered direct offering of pre-funded warrants to Lynx1 Capital

## Summary
- Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.
- Purchaser is Lynx1 Capital Management LP and an affiliated fund, an existing shareholder.
- Net proceeds ~$29.8M for general corporate purposes; closing expected Dec 27, 2024.
- Cash runway extended into Q1 2027 based on net proceeds.

## SEC filing metadata
- accession: 0001193125-24-284671
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524284671/0001193125-24-284671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524284671/d861236d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-284671
- JSON: https://secwatch.observer/filing/0001193125-24-284671.json
- Plain text: https://secwatch.observer/filing/0001193125-24-284671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.